MX2010004488A - Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas. - Google Patents

Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.

Info

Publication number
MX2010004488A
MX2010004488A MX2010004488A MX2010004488A MX2010004488A MX 2010004488 A MX2010004488 A MX 2010004488A MX 2010004488 A MX2010004488 A MX 2010004488A MX 2010004488 A MX2010004488 A MX 2010004488A MX 2010004488 A MX2010004488 A MX 2010004488A
Authority
MX
Mexico
Prior art keywords
methods
modified clostridial
treating chronic
clostridial toxins
neurogenic inflammation
Prior art date
Application number
MX2010004488A
Other languages
English (en)
Inventor
Kei Roger Aoki
Joseph Francis
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2010004488A publication Critical patent/MX2010004488A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L a presente especificación describe toxinas clostridiales modificadas, composiciones que comprenden las toxinas y métodos para tratar inflamación neurogénica crónica en un mamífero utilizando las toxinas clostridiales modificadas y composiciones.
MX2010004488A 2007-10-23 2008-10-21 Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas. MX2010004488A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98202107P 2007-10-23 2007-10-23
US7622808P 2008-06-27 2008-06-27
US9069208P 2008-09-10 2008-09-10
PCT/US2008/080570 WO2009055350A1 (en) 2007-10-23 2008-10-21 Methods of treating chronic neurogenic inflammation using modified clostridial toxins

Publications (1)

Publication Number Publication Date
MX2010004488A true MX2010004488A (es) 2010-06-17

Family

ID=40218954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004488A MX2010004488A (es) 2007-10-23 2008-10-21 Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.

Country Status (11)

Country Link
US (1) US20090104234A1 (es)
EP (1) EP2214696A1 (es)
JP (1) JP2011514307A (es)
KR (1) KR20100088683A (es)
CN (1) CN101903035A (es)
AU (1) AU2008316988A1 (es)
BR (1) BRPI0819212A2 (es)
CA (1) CA2703364A1 (es)
IL (1) IL205280A0 (es)
MX (1) MX2010004488A (es)
WO (1) WO2009055350A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US8198229B2 (en) * 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
MX2012002464A (es) 2009-08-28 2012-03-14 Rinat Neuroscience Corp El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
US20120207734A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
JP6156954B2 (ja) * 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US10633643B2 (en) * 2015-05-15 2020-04-28 Board Of Regents Of The University Of Nebraska Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells
US11117935B2 (en) * 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
CA3036632A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
WO2020020878A1 (en) * 2018-07-23 2020-01-30 Universitetssykehuset Nord-Norge Hf Neurotoxin b for use in the treatment of skin diseases
KR102174197B1 (ko) * 2019-06-12 2020-11-04 주식회사 앤씨비아이티 생산성이 향상된 비독성 프로테아제

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US4189426A (en) * 1976-04-12 1980-02-19 Hoffmann-La Roche, Inc. Recombinant hormonal compositions and method
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
JPS60248659A (ja) * 1984-05-25 1985-12-09 Microbial Chem Res Found ３−〔ｎ−（メルカプトアシル）〕アミノ−４−アリ−ル酪酸誘導体及びそれを有効成分とする鎮痛剤
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5410019A (en) * 1987-09-24 1995-04-25 The Administrators Of The Tulane-Educational Fund Therapeutic peptides
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
ATE138102T1 (de) * 1991-02-19 1996-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von cysteinfreien peptiden
ES2117050T3 (es) * 1991-06-27 1998-08-01 Genelabs Tech Inc Ensayo de cribado para la deteccion de moleculas de union al adn.
US5891842A (en) * 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3122319B2 (ja) * 1994-05-02 2001-01-09 アソシエーティド ユニバーシティーズ，インコーポレイティド 錫−１１７ｍ−含有放射性治療剤
ATE215832T1 (de) * 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5846216A (en) * 1995-04-06 1998-12-08 G & P Technologies, Inc. Mucous membrane infusor and method of use for dispensing medications
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
EP1206554B2 (en) * 1999-08-25 2010-10-20 Allergan, Inc. Activatable recombinant neurotoxins
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
WO2006059093A2 (en) * 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain

Also Published As

Publication number Publication date
JP2011514307A (ja) 2011-05-06
BRPI0819212A2 (pt) 2015-06-16
WO2009055350A1 (en) 2009-04-30
US20090104234A1 (en) 2009-04-23
KR20100088683A (ko) 2010-08-10
CA2703364A1 (en) 2009-04-30
AU2008316988A1 (en) 2009-04-30
EP2214696A1 (en) 2010-08-11
IL205280A0 (en) 2010-12-30
CN101903035A (zh) 2010-12-01

Similar Documents

Publication Publication Date Title
MX2010004488A (es) Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
MX2010004502A (es) Metodos para tratar trastornos neurologicos urogenitales usando toxinas clostridiales modificadas.
WO2010138395A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2010138379A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2010138393A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2010138387A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
IN2012DN02046A (es)
WO2010138392A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2011020114A3 (en) Methods of treating cancer using tachykinin retargeted endopeptidases
WO2010065491A3 (en) Methods of treating inflammatory disorders
WO2011020056A3 (en) Methods of treating cancer using galanin retargeted endpeptidases
MX2009006846A (es) Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias.
WO2011020119A3 (en) Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
WO2011020117A3 (en) Methods of treating cancer using neurotrophin retargeted endopeptidases
WO2013006490A3 (en) Antibodies that specifically bind to tim3
NZ598791A (en) Anti-gcc antibody molecules and related compositions and methods
WO2010003057A3 (en) Treating cancer
MY160041A (en) Compositions and methods for treating parasitic infections
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2008089397A3 (en) Adrb2 cancer markers
MX2011006254A (es) Composiciones aclaradoras de la piel con inhibidores de acetilcolinesterasa.
WO2009048980A3 (en) Emp2 antibodies and their therapeutic uses
WO2010138389A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
WO2007111917A3 (en) Digital media distribution system
WO2010138384A3 (en) Methods of treating chronic neurogenic inflammation using a modified clostridial toxin